UCB To SHAPE Up With Cost-Cutting Plan, Two Years After Schwarz Buy
Executive Summary
UCB is joining the ranks of pharma companies embarking on major cost cutting programs, as the Belgian company decides to focus on specialty markets two years after bulking up via the acquisition of Schwarz Pharma
You may also be interested in...
UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease
UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.
UCB’s Vimpat Falters In Diabetic Pain
Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.